Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Depreciation and Depletion (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Depreciation and Depletion for 6 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 11.11% year-over-year to $1.0 million, compared with a TTM value of $3.9 million through Dec 2025, up 11.43%, and an annual FY2025 reading of $3.9 million, up 11.43% over the prior year.
  • Depreciation and Depletion was $1.0 million for Q4 2025 at Cytek Biosciences, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.0 million in Q3 2024 and bottomed at $167000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $635950.0, with a median of $700000.0 recorded in 2023.
  • The sharpest move saw Depreciation and Depletion surged 187.39% in 2021, then changed 0.0% in 2025.
  • Year by year, Depreciation and Depletion stood at $342000.0 in 2021, then surged by 51.75% to $519000.0 in 2022, then soared by 54.14% to $800000.0 in 2023, then grew by 12.5% to $900000.0 in 2024, then increased by 11.11% to $1.0 million in 2025.
  • Business Quant data shows Depreciation and Depletion for CTKB at $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $1.0 million in Q2 2025.